A soluble form of the interleukin-6 family signal transducer gp130 is dimerized via a C-terminal disulfide bridge resulting from alternative mRNA splicing.

[1]  Stefan Rose-John,et al.  IL-6 biology: implications for clinical targeting in rheumatic disease , 2014, Nature Reviews Rheumatology.

[2]  J. Scheller,et al.  Recombinant p35 from Bacteria Can Form Interleukin (IL-)12, but Not IL-35 , 2014, PloS one.

[3]  J. Scheller,et al.  Alternative Intronic Polyadenylation Generates the Interleukin-6 Trans-signaling Inhibitor sgp130-E10* , 2014, The Journal of Biological Chemistry.

[4]  J. Scheller,et al.  Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. , 2014, Seminars in immunology.

[5]  J. Scheller,et al.  Interleukin-6 and interleukin-11: same same but different , 2013, Biological chemistry.

[6]  J. Scheller,et al.  Minimal Interleukin 6 (IL-6) Receptor Stalk Composition for IL-6 Receptor Shedding and IL-6 Classic Signaling , 2013, The Journal of Biological Chemistry.

[7]  S. Rose-John.  IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6 , 2012, International journal of biological sciences.

[8]  H. Hermanns,et al.  Plasticity and cross-talk of interleukin 6-type cytokines. , 2012, Cytokine & growth factor reviews.

[9]  S. Rose-John,et al.  Hitting a complex target: an update on interleukin-6 trans-signalling , 2012, Expert opinion on therapeutic targets.

[10]  J. Scheller,et al.  Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor* , 2011, The Journal of Biological Chemistry.

[11]  J. Scheller,et al.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. , 2011, The Journal of clinical investigation.

[12]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[13]  J. Scheller,et al.  Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding* , 2011, The Journal of Biological Chemistry.

[14]  C. Fielding,et al.  Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. , 2006, Arthritis and rheumatism.

[15]  Stefan Rose-John,et al.  Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane , 2005, Protein science : a publication of the Protein Society.

[16]  C. Hölscher.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases , 2004, Medical Microbiology and Immunology.

[17]  M. Neurath,et al.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.

[18]  K. Nakao,et al.  Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. , 2000, The Journal of clinical investigation.

[19]  S. Rose-John,et al.  IL-6 Type Cytokine Receptor Complexes: Hexamer, Tetramer or Both? , 1999, Biological chemistry.

[20]  B. Klein,et al.  Cloning and expression of an alternatively spliced mRNA encoding a soluble form of the human interleukin‐6 signal transducer gp130 1 , 1997, FEBS letters.

[21]  S. Rose-John,et al.  A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.

[22]  T. Kishimoto,et al.  Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.

[23]  Stephen K. Smith,et al.  Stage-specific expression of cytokine and receptor messenger ribonucleic acids in human preimplantation embryos. , 1995, Biology of reproduction.

[24]  S. Ziegler,et al.  Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Yancopoulos,et al.  Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. , 1993, Blood.

[26]  P. Heinrich,et al.  Structure-function analysis of interleukin-6 utilizing human/murine chimeric molecules. Involvement of two separate domains in receptor binding. , 1993, The Journal of biological chemistry.